Anti-thymocyte globulin (rabbit) is under clinical development by Neovii Pharmaceuticals and currently in the Phase III in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect Anti-thymocyte globulin (rabbit)’s likelihood of approval (LoA) and phase transition for Graft Versus Host Disease (GVHD) took place on 01 Apr 2022, which increased the likelihood that the drug progresses to the next phase in its clinical pathway and increased the likelihood of final approval for this indication.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their Anti-thymocyte globulin (rabbit) Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

Anti-thymocyte globulin (rabbit) overview

Anti-thymocyte globulin (Rabbit) (ATG, Grafalon, EZ-2053) is a polyclonal antibody. It is formulated as concentrate solution for injection, administered through intravenous route of administration. Anti-thymocyte globulin is indicated in combination with other immunosuppressive drugs to suppress the competent immune cells that are the cause of acute rejection in kidney transplant patients or of graft versus host disease, indicated in combination with other immunosuppressive drugs (eg, glucocorticosteroids, purine antagonists, calcineurin inhibitors and mTOR inhibitors), to reinforce immunosuppression preoperatively, perioperative or postoperative immediately after renal transplantation, treatment of acute rejection resistant to corticosteroids after renal transplantation if methylprednisolone therapy has proved unsatisfactory, for the prevention of graft versus host disease (GVHD) in adults with a pattern of myeloablative conditioning prior to hematopoietic stem cells from peripheral blood or bone marrow of matched unrelated donor, in combination with usual prophylaxis using cyclosporin A/methotrexate.

It is under development for the prevention of moderate to severe chronic GVHD in the US. It was also under development for the prophylaxis of acute pulmonary allograft rejection.

Neovii Pharmaceuticals overview

Neovii Pharmaceuticals is a biopharmaceutical business with a patient-centered objective to create and commercialise innovative, life-changing treatments to enhance outcomes in hemato-oncology, immunological diseases, and transplantation medicine. The company is headquartered in Switzerland.

Quick View Anti-thymocyte globulin (rabbit) LOA Data

Report Segments
  • Innovator (NME)
Drug Name
  • Anti-thymocyte globulin (rabbit)
Administration Pathway
  • Intravenous
Therapeutic Areas
  • Immunology
Key Developers
Highest Development Stage
  • Marketed

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.